Flucytosine
Flucytosine
CLINICAL USE
Antifungal agent
DOSE IN NORMAL RENAL FUNCTION
100–200 mg/kg per day in 4 divided doses
PHARMACOKINETICS
Molecular weight                           :129.1 %Protein binding                           :2–4 %Excreted unchanged in urine     : 90 Volume of distribution (L/kg)       :0.65–0.91half-life – normal/ESRD (hrs)      :3–6/75–200 DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20–40 50 mg/kg 12 hourly 10 to 20     : 50 mg/kg 24 hourly <10           : 50 mg/kg then dose according to levels. Dose of 0.5–1 g daily is usually adequate DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Dialysed. Give 50 mg/kg daily in 4 divided doses. Monitor levels HD                     :Dialysed. Dose as in GFR <10           : mL/min, given post dialysis. Monitor trough level pre dialysis, and reduce post-dialysis dose accordinglyHDF/high flux   :Dialysed. Dose as in GFR <10           : mL/min, given post dialysis. Monitor trough level pre dialysis, and reduce post-dialysis dose accordinglyCAV/VVHD      :Dialysed. Give dose as in GFR 10 to 20 mL/min and monitor blood levels, pre dose IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsCytarabine: concentration of flucytosine possibly reduced ADMINISTRATION
Reconstition
– Route
IV peripherally through a blood filter Rate of Administration
20–40 minutes Comments
– OTHER INFORMATION
Monitor blood levels 24 hours after therapy commences. Pre-dose level 25–50 mg/L is usually adequate. Do not exceed 80 mg/L250 mL intravenous flucytosine infusion contains 34.5 mmol sodiumBone marrow suppression more common in patients with renal impairmentTablets available on named patient basis onlyCan be given IP at a dose of 50 mg/L
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home